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Abstract
Glycoprotein hormone receptors contain a large extra-
cellular domain that is encoded by multiple exons, facili-
tating the possibility of expressing alternatively spliced
transcripts. We have cloned two new splice variants of the
rat follicle-stimulating hormone (FSH) receptor gene:
FSH-R1 and FSH-R2. The splice variant FSH-R1 diVers
from the full-length FSH receptor mRNA by the inclu-
sion of a small extra exon between exons 9 and 10.
FSH-R2 lacks the first three base pairs of exon 4, contains
an extra exon between exons 4 and 5, and has an extended
3*-untranslated region. According to the predicted open
reading frames, both mRNAs encode truncated FSH
receptor proteins, consisting of the entire extracellular
domain (FSH-R1) or the amino-terminal half of the
extracellular domain (FSH-R2), and are expressed at a low
level in testes and ovaries. The levels of expression of the
FSH-R1 and FSH-R2 mRNAs in the gonads show a
constant ratio to the expression level of the full-length
FSH receptor mRNA. Furthermore, in vitro co-expression
of either one of the truncated proteins with the full-length
FSH receptor in COS1 cells did not aVect signal transduc-
tion through the full-length FSH receptor. The absence of
a function of the truncated FSH receptors in FSH signal
transduction in vitro, and the lack of diVerential regulation
of the alternative transcripts, indicate that there is no
clear function for alternative splicing of the FSH receptor
pre-mRNA in the postnatal testis and the cycling
adult ovary.
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Introduction
The gonadotropins luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) have key roles in the regula-
tion of ovarian and testicular functions (extensively
reviewed in Carr 1992, GriYn & Wilson 1992). The LH
receptor (Loosfelt et al. 1989, McFarland et al. 1989) and
the FSH receptor (Sprengel et al. 1990) belong to the large
family of GTP-binding protein (G protein)-coupled
receptors and are located at the plasma membrane of
the target cells. Together with the thyroid-stimulating
hormone (TSH) receptor (Parmentier et al. 1989), these
receptors form a subgroup of glycoprotein hormone recep-
tors because they have a large glycosylated extracellular
domain of approximately the same size as the transmem-
brane domain, which is in contrast to almost all other G
protein-coupled receptors. This extracellular domain is
involved in hormone binding (Braun et al. 1991) and is
encoded by multiple exons (Gross et al. 1991, Heckert
et al. 1992, Tsai-Morris et al. 1990). The first ten exons of
the LH receptor gene encode the extracellular domain,
whereas the last exon encodes both the transmembrane
and the intracellular domains (Tsai-Morris et al. 1990). In
the FSH and TSH receptor genes, each consisting of ten
exons (Gross et al. 1991, Heckert et al. 1992), the
extracellular domain is encoded by the first nine exons.
Shortly after the gonadotropin receptor cDNAs were
cloned, it became apparent that alternatively spliced tran-
scripts are co-expressed with the full-length receptor
mRNA transcript (reviewed in Themmen et al. 1994,
Misrahi et al. 1996, O’Shaughnessy et al. 1996). Alterna-
tive transcripts encode truncated receptors with two
distinct structures: either receptor proteins containing the
signal peptide and a part of the extracellular domain but no
transmembrane domain, or receptor proteins that lack a
part of the extracellular or intracellular domain but still
contain the transmembrane domain. Of the latter form, a
C-terminally truncated ovine-FSH receptor has been
described (Sairam et al. 1996). The protein has a mem-
brane location, binds FSH, but is unable to transduce
signal. In vitro co-expression of this protein together with
the full-length FSH receptor results in attenuation of
full-length receptor signal transduction (Sairam et al.
1996).
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Truncated receptor proteins that lack the transmem-
brane domain may be secreted, although this remains
equivocal. Transient expression of truncated LH receptors
in HEK293 cells did not result in secretion (Xie et al.
1990), whereas a similar protein showed partial secretion
from transiently transfected COS7 cells (VuHai-LuuThi
et al. 1992). The latter authors also showed that the
secreted protein, when co-expressed with the full-length
receptor molecule, enhanced human chorionic gonadotro-
pin (hCG)-induced cAMP production (VuHai-LuuThi
et al. 1992). Another function of alternative splicing of the
gonadotropin receptors may be the regulation of receptor
gene expression at the post-transcriptional level. In pre-
natal female rats, splice variants of the LH receptor gene
are expressed, whereas the full-length receptor transcript
could not be detected (Sokka et al. 1992). Expression
of this transcript could only be detected from day 7 of
neonatal life onward. In this situation, expression of a
functional LH receptor during the perinatal period is
prevented, despite continuous transcription of the LH
receptor gene (Sokka et al. 1992). For the LH receptor in
the testis and the FSH receptor in the testis and the ovary,
a delay of only 2 days was observed before the appearance
of the full-length receptor transcript (Rannikki et al. 1995,
Zhang et al. 1994). Functional studies on splice variants of
the related TSH receptor have mainly addressed possible
involvement of secreted receptor proteins in the develop-
ment of Graves’ disease (Ligett et al. 1991, Graves et al.
1992, 1995). To date, no clear evidence exists that shows
the involvement of circulating truncated TSH receptors in
this autoimmune disease.
In the present paper, we report the cloning of two splice
variants of the rat FSH receptor gene. In view of the
possible biological importance of truncated glycoprotein
hormone receptors, we have studied the expression and
putative function of these FSH receptor variants.
Materials and Methods
Cloning of FSH-R1 and FSH-R2
A rat Sertoli cell directional cDNA library (Baarends
et al. 1994) in lambda ZAP II (Stratagene, Westburg,
Leusden, The Netherlands) consisting of 1·5#106
independent clones was screened with two rat FSH
receptor cDNA probes, corresponding to the 5*-part
(positions "71 to 791) and the 3*-part (positions 793
to 2095) of the FSH receptor cDNA (Sprengel et al.
1990). Æ-[32P]dATP (Amersham, ’s Hertogenbosch, The
Netherlands)-labeled probes (Feinberg & Vogelstein 1983)
were used to screen approximately 106 plaques (Sambrook
et al. 1989). Two positive plaques were purified during
two subsequent rescreen rounds. pBluescript SK plasmids
containing the positive clones were isolated according
to the in vivo excision protocol described by the
manufacturer.
The positive clones were subjected to restriction
enzyme analysis and compared with the published FSH
receptor cDNA (Sprengel et al. 1990). Nucleotides and
amino acids are numbered according to this published rat
FSH receptor cDNA. Sequence analysis was performed of
both clones in one orientation according to the dideoxy
chain termination method (Sanger et al. 1977), using
primers derived from cDNA sequences. Sequences that
diVered from the published cDNA were sequenced in
both orientations. Both clones were found to be splice
variants of the FSH receptor gene. No attempts were
made to screen the library again in order to obtain a
full-length (wild type) FSH receptor cDNA, as this cDNA
could easily be constructed by exchanging the 384 base
pairs NcoI/Bsu36I fragment (positions 704 to 1088) of
FSH-R2 into FSH-R1 (see Fig. 1). Expression vectors
were constructed by cloning the EcoRI/BamHI fragments
of full-length FSH receptor, FSH-R1 and FSH-R2
(positions "71 to 2095) into the EcoRI/BamHI sites of
pSG5 (Green et al. 1988).
RNA preparation and RNase protection assay
Wistar rats, locally bred, were maintained under controlled
conditions (20–23 )C, lights on from 0500 to 1900 h).
Animal care was in accordance with the Guidelines on
the Handling and Training of Laboratory Animals
(Universities Federation of Animal Welfare).
Total testes were isolated from 21-day-post-coitus (p.c.)
fetuses, 21-day-old immature rats and 56-day-old mature
rats, and snap frozen in liquid nitrogen. Folliculogenesis
and ovulation were induced in 30-day-old immature rats
by injecting (s.c.) 30 IU pregnant mare serum gonado-
tropin (PMSG; Folligonan, Intervet, Boxmeer, The
Netherlands) followed, 56 h later, by injecting (s.c.) 10 IU
hCG (Pregnyl; Organon International NV, Oss, The
Netherlands). Ovaries were isolated and snap frozen in
liquid nitrogen 0, 24, 48, 72 and 168 h after the PMSG
injection. Sertoli cells were isolated from 21-day-old rats
(Themmen et al. 1991), cultured for 4 days in the absence
of FSH, and then stimulated for 4 h with 500 ng/ml ovine
FSH-S16 (NIH, Bethesda, MD, USA) in order to down-
regulate FSH receptor mRNA levels, as described pre-
viously (Themmen et al. 1991). Total RNA was isolated
from tissues and isolated cells using the LiCl/urea method
(AuVray & Rougeon 1980).
RNase protection assays were performed using
FSH-R1 and FSH-R2 specific probes. For FSH-R1, a
485-base pair NcoI/EcoRV FSH-R1 cDNA fragment
encompassing a part of exon 9 (from position 704), exon
9A and a part of exon 10 (to position 1068) was subcloned
in pBluescript KS (Stratagene) and used to generate
Æ-[32P]UTP (Amersham)-labeled anti-sense transcripts
in vitro. For FSH-R2, a 291-base pair HindIII/PvuII
FSH-R2 cDNA fragment was used. This fragment
encompasses a part of exon 2 (from position 168), exon 3,
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exon 4 without the first three base pairs, exon 4A and a
part of exon 5 (to position 406). Æ-[32P]UTP-labeled
anti-sense transcripts were generated in vitro (Sambrook
et al. 1989), using T7 RNA polymerase (Stratagene).
Approximately 5#104 c.p.m. FSH-R1 or FSH-R2 probe
was mixed with 25 µg total RNA in a total volume of
30 µl hybridization mixture containing 40 mM PIPES
(pH 6·4), 1 mM EDTA, 0·4 M NaCl and 80% (v/v)
formamide. Hybridizations were performed overnight at
55 )C. The RNase protection assay was performed as
described (Sambrook et al. 1989).
In vitro expression in COS1 cells
COS1 cells were maintained in DMEM/HAM’s F12
(1 : 1 v/v) (Gibco BRL, Gaithersburg, MD, USA) con-
taining 5% (v/v) fetal calf serum (Sebak, Aidenbach,
Germany), 2#105 IU/l penicillin (Brocades Pharma,
Leiderdorp, The Netherlands) and 0·2 g/l streptomycin
(Radium Farma, Milan, Italy). Cells were seeded at 10%
confluence, incubated in a humidified incubator at 37 )C
and 5% CO2 in air, and split at 80–90% confluence.
One day before transfection, cells were seeded at 15%
confluence in 80 cm2 flasks (Nunc, Roskilde, Denmark).
Calcium phosphate precipitate transfections were per-
formed as described (Chen & Okayama 1987). Each flask
received 1 ml precipitate containing 10 µg expression
plasmid (5 µg expression vector with 5 µg empty vector
(pSG5) for expression of the cDNAs alone, or 5 µg
full-length FSH receptor expression vector with either
5 µg FSH-R1 or FSH-R2 expression vector for
co-expression of the cDNAs), and 10 µg pTZ19R
(Pharmacia, Uppsala, Sweden) as carrier DNA. In order to
perform hormonal stimulations, Western blotting and
[125I]FSH-binding assays with the same batch of trans-
fected cells, several 80 cm2 flasks were transfected with
each combination of expression vectors, pooled 2 days after
transfection by harvesting the cells with 0·02% EDTA
in PBS without trypsin, diluted (1 : 1), and seeded
into diVerent tissue culture dishes. Experiments were
performed 3 days after transfection.
FSH-induced cAMP production was determined in
quadruplicate in 12-well plates (Costar, Cambridge,
MA, USA). Cells were stimulated with diVerent doses
of recombinant human FSH (Org32489; Organon
International NV) in medium without serum, but con-
taining 25 mM HEPES pH 7·5 (Gibco), 0·1% (w/v) BSA
(Sigma, St Louis, MO, USA), and 0·2 mM isobutyl-
methylxanthine (Sigma). After stimulation for 2 h, cAMP
production was determined in the medium (Stoof et al.
1987). To test the eVects of the truncated proteins on FSH
signal transduction, conditioned media were prepared by
incubation of the cells for 18 h. Part of this medium was
removed from each well, pooled and used to prepare the
stimulation medium as described above.
For Western blotting, cells were cultured in 25 cm2
flasks (Nunc), and washed three times at 4 )C with
HEPES-buVered saline (25 mM HEPES pH 7·5, 150 mM
NaCl, 0·9 mM CaCl). Cells from each flask were lysed in
300 µl lysis buVer (20 mM Tris pH 7·5, 150 mM NaCl,
1 mM EDTA, 0·5% Triton X100, 10% glycerol, 0·1 mg/
ml phenylmethylsulfonylfluoride, 1 µg/ml leupeptin,
1 µg/ml aprotinin) for 10 min at 4 )C on a rocking
platform. Lysates were stored at"20 )C and subsequently
used for Western blotting.
Human [125I]FSH (DuPont/NEN, Du Pont de
Nemours GmbH, Dreieich, Germany) binding was per-
formed using partially purified membrane preparations
(Ketelslegers & Catt 1978) isolated from cells cultured in
80 cm2 flasks (Nunc).
Antibodies and Western blotting
Peptide SP297, corresponding to residues 15–32 (CQD-
SKVTEIPTLPRNAI) of the rat FSH receptor, was syn-
thesized (Atherton & Sheppard 1989) and used to raise a
polyclonal antiserum directed against the N-terminus
of the FSH receptor. Three milligrams peptide was
coupled to 3 mg m-maleimidobenzoyl-N-hydroxy-
succinimide (Pierce, Rockford, IL, USA)-activated
keyhole limpet hemocyanin (Calbiochem, La Jolla, CA,
USA) according to the manufacturer’s instructions. The
coupled peptide (100 µg) was mixed with an equal volume
of Freund’s complete adjuvant (Difco, Detroit, MI, USA)
and used to immunize a castrated male New Zealand
White rabbit by subcutaneous injections. Six and twelve
weeks after the initial injection, the rabbit was boosted
with the same amount of coupled peptide mixed with an
equal volume of Freund’s incomplete adjuvant (Difco).
Two weeks after the second boost, the rabbit was bled and
serum was prepared. The resulting polyclonal antiserum
was designated 1601–5. Pre-immune antiserum (1601–0)
was obtained 2 weeks before the start of the immunization
procedure.
Western blotting was performed on a Mini-Protean II
gel electrophoresis and electroblotting system (Biorad,
Hercules, CA, USA). The lysate (10 µl) was mixed with
2·5 µl 5#sample buVer (50 mM Tris pH6·8, 10 mM
DTT, 10% (v/v) glycerol, 2% (w/v) SDS, 8 M urea, and
0·001% bromophenol blue), boiled for 5 min, separated on
a 15% SDS–polyacrylamide gel and blotted onto nitro-
cellulose filters (Schleicher & Schuell, Dassel, Germany),
according to the manufacturer’s instructions. Non-specific
binding sites were blocked for 1 h with 5% (w/v) non-fat
dry milk in PBS–0·1% (v/v) Tween-20, incubated with
antiserum 1601–5 (1 : 1000) in PBS–0·1% Tween-20/1%
non-fat dry milk for 1 h, washed four times for 15 min
with PBS–0·1% Tween-20, incubated with goat-
antirabbit IgG conjugated to horseradish peroxidase
(Sigma) (1 : 4000) in PBS–0·1% Tween-20–1% non-fat
dry milk for 1 h, and washed again four times with
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PBS–0·1% Tween-20. Chemiluminescence detection of
proteins with Luminol (DuPont/NEN) was performed
according to the manufacturer’s instructions. Blots were
exposed to X-ray films (Amersham) for 1 and 60 min.
Results
Cloning of two rat FSH receptor splice variants
To isolate a complete FSH receptor cDNA clone, a rat
Sertoli cell cDNA library was screened with partial FSH
receptor cDNA probes. Two positive plaques (FSH-R1
and FSH-R2) were isolated, sequenced, and compared
with the original rat FSH receptor cDNA (Sprengel et al.
1990) and the genomic organization of the rat FSH
receptor gene (Heckert et al. 1992). This comparison
revealed that both clones do not encode the full-length
FSH receptor, but instead are splice variants of the FSH
receptor gene (Fig. 1a).
The FSH-R1 cDNA is 2487 base pairs in size and
contains a stretch of 121 base pairs at the junction of exons
9 and 10 (Fig. 1b). No sequence similarities could be found
with intron sequences located directly downstream of exon
9 or upstream of exon 10, suggesting that this stretch of
121 base pairs is an alternative exon (exon 9A). The
presence of exon 9A introduces a premature stop in
the open reading frame, which results in truncation of the
receptor protein (Fig. 1b). The FSH-R1 protein contains
nearly the entire extracellular domain and has a calculated
molecular mass of 32 kDa.
The other cDNA, FSH-R2, is 3239 base pairs in size.
The most obvious diVerence compared with the full-
length FSH receptor cDNA is an extension of the 3*-
untranslated region with approximately 800 base pairs,
which is caused by the use of a putative alternative
polyadenylation signal (Fig. 1c). The overlapping parts
between the FSH-R2 3*-untranslated region and the 3*-
untranslated region of the full-length FSH receptor
(Sprengel et al. 1990) are not identical. This diVerence
may be explained by strain diVerences or DNA sequenc-
ing errors, as the 3*-untranslated region of FSH-R2 is
identical to the genomic sequence of the rat FSH receptor
as published by Heckert et al. (1992). FSH-R2 transcripts
lack the first three bases of exon 4, which results in a
change of amino acid residues isoleucine and arginine
(positions 83 and 84 of the original open reading frame)
into one methionine residue in FSH-R2 (Fig. 1d).
Between exons 4 and 5, an additional stretch of 56 base
pairs is present that has no homology with the intron
sequences flanking exons 4 and 5 (Heckert et al. 1992),
indicating that the FSH-R2 transcript also contains an
alternative exon (exon 4A). The open reading frame is
continued throughout exon 4A, but after transition into
exon 5, a frame shift is introduced, resulting in a premature
stop codon (Fig. 1d). FSH-R2 transcripts encode a trun-
cated FSH receptor protein composed of the N-terminal
half of the extracellular domain, with a calculated
molecular mass of 16 kDa.
To verify whether the predicted truncated receptor
proteins can indeed be translated from the isolated tran-
scripts, both clones and the full-length FSH receptor were
transiently expressed in COS1 cells. Total cell lysates were
prepared and subjected to Western blotting (Fig. 2), using
polyclonal antiserum 1601–5, raised against a synthetic
peptide corresponding to amino acid residues 15–32 of the
rat FSH receptor. Full-length FSH receptor protein could
not be detected at the expected size of 80 kDa (Quintana
et al. 1993). Instead, a high-molecular-mass band was
observed that resembled the 240-kDa FSH receptor band
observed by Dattatreyamurty et al. (1992). FSH-R1 and
FSH-R2 appeared as bands of 40 kDa and as a double
band at 16 kDa respectively (Fig. 2).
FSH-R1 and FSH-R2 mRNAs are expressed in testis and
in ovary
DiVerential regulation of the expression of the FSH-R1
and FSH-R2 mRNAs, might provide indications as to
possible functions of the truncated receptor proteins. Many
studies have addressed the expression of both LH and FSH
receptor splice variants (e.g. LaPolt et al. 1991, 1992,
Sokka et al. 1992, Vihko et al. 1992, O’Shaughnessy &
Dudley 1993, O’Shaughnessy et al. 1994, Tena-Sempere
et al. 1994, Veldhuizen-Tsoerkan et al. 1994, Zhang et al.
1994, Rannikki et al. 1995). In these studies, however,
mRNA expression levels were determined with Northern
blotting or reverse transcriptase-polymerase chain reaction
(RT-PCR) assays. Besides being relatively insensitive,
Northern blotting does not readily resolve alternative
transcripts that have only minor diVerences from the
full-length receptor transcripts, such as FSH-R1, and does
not, therefore, seem to be an appropriate tool to investigate
mRNA expression of FSH-R1 and FSH-R2. RT-PCR,
in contrast, does not have these disadvantages, but is not a
quantitative method. To avoid these drawbacks, an exon-
specific RNase protection assay was set up. This technique
is transcript-specific, very sensitive, and quantitative. Fur-
thermore, it is possible to monitor the expression of an
alternative transcript and the full-length FSH receptor
transcript in a single assay.
Examples of the RNase protection assay with the
FSH-R1 and FSH-R2-specific probes are shown in Fig.
3a. Besides the expected bands, protected by the full-
length receptor and the FSH-R1 and FSH-R2 transcripts,
other bands are observed that probably represent other
FSH receptor splice variants. According to their sizes, the
composition of one fragment can be postulated, whereas
the etiology of the two other fragments can not readily be
explained. For RNase protection assays with the FSH-R1
probe, an additional protected fragment was observed with
a size of approximately 270 base pairs. This fragment may
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arise from protection by transcripts that contain additional
sequences between exons 9A and 10, besides the
alternative exon 9A.
One of the roles of the FSH-R1 and FSH-R2 splice
variants may be the modulation of FSH receptor function,
which requires independent regulation from the full-
length FSH receptor mRNA. We therefore determined
RNA expression levels in diVerent physiological situations.
In the female, expression levels were determined in a
synchronized ovarian cycle model. Thirty-day-old imma-
ture rats were stimulated with PMSG, which results in a
synchronized growth of many immature follicles. Twenty-
four and forty-eight hours after PMSG injection, antral
follicles were present (Baarends et al. 1995). During this
follicular growth phase, full-length FSH receptor expres-
sion was relatively high (Fig. 3b; ovary: 0, 24 and 48 h).
Figure 1 Characterization of FSH-R1 and FSH-R2 cDNA clones. (a) Schematic representation of the full-length FSH receptor and the FSH
receptor splice variants FSH-R1 and FSH-R2. Exons are represented by open boxes, additional sequences (exon 9A, exon 4A, and the
extended 3*-untranslated region of FSH-R2) by closed boxes, deletion of the first three bases of exon 4 in FSH-R2 by ˜. The predicted
open reading frames are shown under the RNA sequences; the putative signal peptide and transmembrane segments are indicated
(stippled and hatched boxes respectively). The NcoI and Bsu36I sites, which were used to construct the full-length FSH receptor cDNA,
are also indicated. (b) Sequence comparison of the full-length FSH receptor with FSH-R1. Only relevant sequences are shown: positions
840 to 869 of the full-length receptor. Encoded amino acids are shown in three-character code above or below the nucleotide sequences.
Sequence identity is indicated by vertical lines, and differences from the full-length FSH receptor in bold characters. Stop codons are
indicated by asterisks. (c) Sequence comparison of the full-length FSH receptor with the 3* untranslated region of FSH-R2. Only relevant
sequences are shown: positions 2095 to 2294 of the full-length receptor. Consensus and putative polyadenylation signals are underlined.
See Fig. 1b for further explanation. (d) Sequence comparison of the full-length FSH receptor with exon 4A of FSH-R2. Only relevant
sequences are shown: positions 279 to 425 of the full-length receptor. See Fig. 1b for further explanation.
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Fifty-six hours after PMSG injection, the antral follicles
were induced to ovulate by a single injection with hCG.
Ovulated follicles, that were present 72 h after PMSG
injection, will have developed into corpora lutea at 168 h
after PMSG injection (Baarends et al. 1995). After ovula-
tion, full-length FSH receptor expression was down-
regulated and maintained at a low level (Fig. 3b; ovary: 72
and 168 h). Compared with the expression of full-length
FSH receptor mRNA, the FSH-R1 and FSH-R2 mRNA
levels were very low, and changed in exact concordance
with the changes in the expression of full-length receptor
transcript.
In male rats, the splice variant mRNA expression levels
were investigated during testicular development. Testes
were isolated from rats at three diVerent ages, representing
diVerent stages of testicular development: fetal rats (21-
days p.c.), immature rats (21-days old) and young-adult
rats (56-days old). Earlier fetal stages were not included, as
large amounts (25 µg) of RNA could not be isolated from
these testes. During testicular development, full-length
FSH receptor mRNA expression was found to remain
constant per total amount of RNA (Fig. 3b; testis). These
findings are in contrast with those of Heckert & Griswold
(1991), who observed decreased FSH receptor mRNA
expression in 60-day-old rats, which was probably caused
by increased numbers of germ cells in the testis. Although
we cannot readily explain this diVerence, strain diVerences
between the animals used in these studies may have a role.
As was observed in the ovary, the splice variants showed a
very low level of expression, with a pattern similar to the
expression pattern of full-length FSH receptor mRNA.
Full-length FSH receptor mRNA can clearly be
demonstrated (Fig. 3b; SC) in cultures of Sertoli cells. In
agreement with previous results (Themmen et al. 1991),
stimulation of these cells for 4 h with FSH resulted
in an almost complete down-regulation of FSH receptor
mRNA. The low expression levels of the FSH-R1 and
FSH-R2 splice variants were concomitantly down-
regulated by incubation of Sertoli cells with FSH.
FSH-R1 and FSH-R2 do not aVect full-length FSH receptor
signal transduction
The experiments described above demonstrated that both
FSH-R1 and FSH-R2 are expressed in ovaries and in
testes, and that their expression levels, when compared
with the full-length receptor mRNA expression level, are
low and not diVerentially regulated. A low and constant
co-expression of truncated receptor proteins together with
the full-length receptor molecule could play a part in
modulation of FSH sensitivity of Sertoli and granulosa
cells. The truncated receptors might present the ligand to
the full-length receptor and increase the bioavailability of
FSH, as has been described for truncated LH receptor
molecules (VuHai-LuuThi et al. 1992). Alternatively, the
proteins might lower FSH bioavailability by sequestering
the ligand away from the full-length receptor.
The eVects of FSH-R1 and FSH-R2 on the bioavail-
ability of FSH were tested in co-expression experiments.
The splice variants were transiently expressed in COS1
cells together with the full-length FSH receptor. Two days
after transfection, medium was renewed and cells were
incubated overnight in order to allow possible secretion of
the truncated receptors into the medium. Subsequently,
the cells were stimulated by adding diVerent doses of ovine
FSH to the medium and cAMP production was measured
over a 2-h period. In the same experiment, using the same
batch of transfected cells, the expression of the truncated
proteins was verified on Western blots (Fig. 2), and
full-length FSH receptor expression was determined in
[125I]FSH-binding assays. Furthermore, the media of the
transfected cells were subjected to Western blotting to
determine the presence of truncated proteins (data not
shown). Although these Western blots proved the pres-
ence of truncated proteins in the medium, parallel controls
for the cytoplasmic/nuclear protein MAP kinase were also
positive. This indicates that truncated proteins found in
the medium may result from leakage from damaged cells.
It was observed that expression of the truncated receptor
proteins, in the absence of full-length FSH receptor, did
not result in FSH-induced cAMP production (Fig. 4 left
Figure 2 Western blotting of full-length FSH receptor, FSH-R1 and
FSH-R2. FSH receptor expression vectors or empty vector pSG5
(control) were transiently expressed in COS1 cells. Proteins were
isolated, separated on a 15% SDS–PAGE gel, and subjected to
Western blotting using polyclonal antiserum 1601–5. FSH-R,
FSH-R1 and FSH-R2 indicate cells that were transfected with the
different receptor constructs. FSH-R+FSH-R1 and FSH-R+FSH-R2
indicate co-transfection experiments. Positions of molecular mass
standards are given at the left. Arrows indicate bands that
correspond to the different FSH receptor isoforms.
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panel). On the other hand, maximal stimulation of cells
expressing the full-length receptor alone resulted in a
sevenfold increase in cAMP production. Co-expression of
either one of the truncated receptor proteins with the
full-length receptor resulted in similar dose–response
curves, however, basal levels of cAMP varied between
cells transfected with diVerent constructs, with the pSG5
control showing the highest basal level (Fig. 4 left panel).
Over-expression of proteins in COS1 cells may negatively
aVect the activity of the adenylyl cyclase enzyme.
Therefore, we calculated cAMP productions for each
combination of constructs as net increase. Furthermore,
by measuring [125I]FSH binding, it was found that
co-expression of FSH-R2 resulted in a minor decrease in
full-length FSH receptor binding sites. Co-expression
with FSH-R1 had a more pronounced eVect: a 30%
reduction of the number of full-length FSH receptor
binding sites (data not shown). These reductions may be
due to competition for translation and post-translational
modification proteins, although it cannot be excluded that
co-expression of the splice variants aVects binding of FSH
to full-length FSH receptor in the binding assay. To
correct for diVerences in full-length FSH receptor expres-
sion, net cAMP production by cells that were transfected
with full-length FSH receptor in the absence or presence
of either FSH-R1 or FSH-R2 was corrected for the
number of full-length FSH receptor molecules expressed,
as determined in the binding assay. These calculations
resulted in comparable FSH-induced cAMP production
values for full-length FSH receptor alone, and for the
full-length FSH receptor in combination with either one
of the splice variants (Fig. 4 right panel).
Discussion
The present paper describes the cloning of alternative
transcripts, FSH-R1 and FSH-R2, of the rat FSH receptor
(a) (b)
Figure 3 Full-length FSH receptor, FSH-R1 and FSH-R2 mRNA expression in ovary, testis, and Sertoli cells. (a) Examples of RNase
protection assays of 21-day-old Sertoli cell RNA using FSH-R1 and FSH-R2-specific probes. On the left, the compositions of the protected
fragments are indicated. The two bands that could not unequivocally be explained are indicated by question marks. The compositions of
the probes are indicated at the right; vector sequences are indicated by zigzags. (b) Total RNA, isolated from ovaries of PMSG/hCG-
treated immature rats (ovary), from testes of different ages (testis), or from Sertoli cells cultured for 4 h in the absence or presence of
500 ng/ml FSH (SC) were subjected to RNase protection assays with FSH-R1 and FSH-R2-specific probes. Protected fragments
representing full-length FSH receptor, FSH-R1, or FSH-R2 mRNA expression are shown. FSH-R1 and FSH-R2 closely follow the mRNA
expression pattern of the full-length FSH receptor.
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gene. Compared with the full-length FSH receptor
cDNA, both transcripts contain extra sequences, which
are located at an exon–exon boundary and are not
homologous to flanking intron sequences (Heckert et al.
1992). This indicates that these sequences are spliced in as
separate exons and do not result from the use of cryptic
splice sites. FSH-R2 contains an alternative exon at the
same position as the human FSH-R 5–10 transcript
described by Kelton et al. (1992); however, it is unlikely
that there is any evolutionary relationship between these
alternative exons, as no sequence similarities could be
found. The deletion of the first three nucleotides of exon
4 in FSH-R2 transcripts is probably due to the use of a
cryptic splice acceptor site. The minimal sequence for a
splice acceptor site is AG (Padgett et al. 1986), which is
present in both the original and the alternative site. The
same pyrimidine stretch 5* of the splice acceptor site can
be used for both sites.
On Western blots, the full-length FSH receptor
appeared as a high-molecular-mass band. This is similar
to bovine FSH receptor Western blots described by
Dattatreyamurty et al. (1992), who identified the receptor
as a 240-kDa band. The high-molecular-mass appearance
may be due to aggregation of proteins under the applied
Western blotting conditions. The FSH-R1 protein, with a
calculated molecular mass of 32 kDa, appeared as a band of
approximately 40 kDa on Western blots. This diVerence
may be explained by glycosylation of the protein, as two
consensus N-linked glycosylation sites are present in this
protein (Sprengel et al. 1990), although no experiments
were conducted to investigate this matter further.
FSH-R2 protein, which does not contain these N-linked
glycosylation sites, appeared as a double band of the
calculated molecular mass (16 kDa). The double band
appearance of FSH-R2 is puzzling: no internal translation
initiation codons, which would result in translation of a
protein still containing the N-terminal epitope, are
present. An explanation might be that the double band
arises from partial signal peptide cleavage, or that second-
ary structures may persist that were not denatured
completely.
Many studies have been performed of FSH and LH
receptor splice variants (reviewed by Themmen et al.
1994, Misrahi et al. 1996, O’Shaughnessy et al. 1996), but
only two studies have addressed possible functional roles
of truncated receptors (Sairam et al. 1996, VuHai-LuuThi
et al. 1992). The study by VuHai-LuuThi et al. (1992)
dealt with a truncated, transmembrane domain-lacking
form of the LH receptor. This truncated receptor
enhanced hCG-induced cAMP production, when tran-
siently co-expressed with the full-length receptor in
COS7 cells. In contrast to this, results reported here
indicate that co-expression of the FSH-R1 and FSH-
R2 splice variants with the full-length FSH receptor does
not aVect FSH signal transduction. Even in the presence of
large amounts of truncated receptor protein that can be
Figure 4 In vitro co-expression of full-length FSH receptor with either FSH-R1 or FSH-R2
in COS1 cells. FSH receptor expression vectors or empty vector pSG5 (control) were
transfected into COS1 cells as described in Materials and Methods. Cyclic AMP
production, upon stimulation with recombinant human FSH, was measured in the medium
and expressed as pmol/well (left panel) or expressed in arbitrary units after correction for
basal cAMP values and the number of full-length FSH receptor binding sites (right panel).
+, pSG5; (,), full-length FSH receptor alone; (0), FSH-R1 alone; (1), FSH-R2 alone;
(4), full-length FSH receptor and FSH-R1; (5), full-length FSH receptor and FSH-R2.
Co-expression of FSH-R1 or FSH-R2 did not have an effect on FSH signal transduction
through the full-length receptor.
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reached in these in vitro co-expression experiments, no
increase in cAMP production could be observed. Produc-
tion of cAMP in the presence of maximal stimulating doses
of FSH seemed to be slightly greater in cells co-expressing
full-length FSH receptor and the splice variants than in
cells that express full-length FSH receptor alone. How-
ever, this eVect was not statistically significant and we
conclude that co-expression of full-length FSH receptor
with either FSH-R1 or FSH-R2 does not aVect full-
length FSH receptor signal transduction. These data,
together with the low and non-diVerentially regulated
mRNA expression levels, indicate that alternative splicing
of the FSH receptor pre-mRNA may not have a function.
The other study that addressed possible functional roles
of truncated receptor molecules (Sairam et al. 1996) dealt
with a C-terminally truncated, membrane-bound form
of the ovine-FSH receptor. This receptor acts as a domi-
nant negative regulator of FSH signal transduction in
co-expression experiments. The functional role assigned to
this truncated FSH receptor may be explained by its
membrane location. High expression levels of truncated
proteins may be reached through accumulation of the
protein in the membrane. Furthermore, this truncated
receptor form is located near the functional full-length
receptor. FSH-R1 and FSH-R2, on the other hand, may
be secreted and then diluted in the extracellular space.
Another function of alternative splicing of gonadotropin
receptors may be regulation of receptor gene expression at
the post-transcriptional level – that is, the prevention of
the synthesis of full-length, functional FSH receptors, as
has been described for LH receptor expression during
ovarian development (Sokka et al. 1992). We could not
observe diVerential regulation of the FSH-R1 and FSH-
R2 splice variants in the postnatal gonads: in ovaries
during the cycle, in testes of diVerent ages, and in cultured
Sertoli cells during FSH-induced down-regulation of FSH
receptor mRNA, the expression levels of both alternative
transcripts showed a constant ratio to the expression level
of full-length FSH receptor mRNA. If, indeed, alternative
splicing of gonadotropin receptor mRNAs is a mechanism
that is involved in developmental control of gonadotropin
receptor expression, the splice variants FSH-R1 and
FSH-R2 may result from incomplete inhibition of this
mechanism at later developmental stages.
In conclusion, we report the cloning and characteriz-
ation of two splice variants of the FSH receptor pre-
mRNA. Although both variants may be functional and
encode truncated FSH receptor isoforms, they do not
appear to have a clear role in FSH signal transduction.
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